Form 4: Immunovant's Chief Legal Officer, Mark S. Levine, Reports Sale of Shares to Cover Tax Obligations

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., reports the sale of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On August 21, 2024, Mark S. Levine, the Chief Legal Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations.
• The sales were mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction.
• A total of 3,164 shares were sold at a weighted average price of $31.84, with individual prices ranging from $31.26 to $32.25 per share.
• An additional 131 shares were sold at a weighted average price of $32.32, with individual prices ranging from $32.28 to $32.37 per share.
• Following these transactions, Levine beneficially owns 330,099 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by a company officer could have a minor impact on shareholder sentiment, although it is primarily driven by tax obligations.

Key Dates